Società Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

TEVA

IL0006290147

Prodotti farmaceutici

Consensus Analisti

Attività

Vendite per attività

Vendite per regione

Dirigenti

Amministratori

Classe di azioni

Azionisti

Partecipazioni

Coordinate società

Società del gruppo

Settore

Vendite per regione

Rating per Teva Pharmaceutical Industries Limited

Revisioni EPS

Utili trimestrali - Indice di sorpresa

Settore Prodotti farmaceutici - Altri

Mercato chiuso - TEL AVIV STOCK EXCHANGE Altri mercati azionari 13:24:08 25/04/2024			Variaz. 5gg	Var. 1 gen.
4.933 ^ILa	+0,98%		-0,90%	+29,31%

17/04	Alvotech e Teva annunciano l'approvazione da parte della FDA statunitense di SELARSDI (ustekinumab-aekn), biosimilare di Stelara (ustekinumab)	CI
11/04	L'unità farmaceutica di Teva afferma che lo studio in fase avanzata in Cina di Ajovy per la prevenzione dell'emicrania ha raggiunto gli endpoint primari e secondari	MT

Teva Pharmaceutical Industries Ltd è un'azienda farmaceutica con sede in Israele. L'azienda opera attraverso tre segmenti: Nord America, Europa e Mercati internazionali. Ogni segmento aziendale gestisce l'intero portafoglio di prodotti nella propria regione, compresi i prodotti generici, quelli speciali e quelli da banco (OTC). Oltre a questi tre segmenti, la Società svolge altre attività, principalmente la vendita di ingredienti farmaceutici attivi (API) a terzi, alcuni servizi di produzione a contratto e una piattaforma di out-licensing che offre un portafoglio di prodotti ad altre aziende farmaceutiche attraverso la sua affiliata Medis.

Numero di dipendenti: 35 737

USD in Milioni	2022	Peso	2023	Peso	Delta
Generics, Innovative Medicines and Over-the-counter Products 100,0 %	14 925	100,0 %	15 846	100,0 %	+6,17%

USD in Milioni	2022	Peso	2023	Peso	Delta
North America 51,3 %	7 452	49,9 %	8 124	51,3 %	+9,02%
Europe 30,5 %	4 525	30,3 %	4 837	30,5 %	+6,90%
International 12,4 %	1 903	12,8 %	1 958	12,4 %	+2,89%
Global 5,8 %	1 045	7,0 %	926	5,8 %	-11,39%

Dirigenti	Titolo	Età	Da
Richard Francis CEO	Chief Executive Officer	55	01/01/23
Eli Kalif DFI	Director of Finance/CFO	51	22/12/19
Eric Hughes CTO	Chief Tech/Sci/R&D Officer	-	01/08/22
Eric Drapé COO	Chief Operating Officer	62	01/01/13
Kathleen Veit CMP	Compliance Officer	-	01/01/10
Amir Elstein BRD	Director/Board Member	67	01/01/95
Yael Ashman IRO	Public Communications Contact	-	01/09/09
Ran Meir IRC	Investor Relations Contact	-	-
Amir Weiss AUD	Comptroller/Controller/Auditor	47	01/06/12
Dov Bergwerk SEC	Corporate Secretary	-	-

Amministratori	Titolo	Età	Da
Gerald Lieberman BRD	Director/Board Member	77	01/09/15
Janet Vergis BRD	Director/Board Member	60	09/06/20
Sol Barer CHM	Chairman	76	01/01/15
Roberto Mignone BRD	Director/Board Member	52	14/07/17
Amir Elstein BRD	Director/Board Member	67	01/01/95
Rosemary Crane BRD	Director/Board Member	64	01/09/15
Richard Francis CEO	Chief Executive Officer	55	01/01/23
Perry Nisen BRD	Director/Board Member	68	14/07/17
Tal Zaks BRD	Director/Board Member	58	01/10/21
Ronit Satchi-Fainaro BRD	Director/Board Member	52	01/06/18

	Voto	Quantità	Flottante	Autocontrollo	Flottante totale
Azione A	1	1 238 640 597	1 111 231 488 ( 89,71 %)	106 000 000 ( 8,558 %)	89,71 %

Nome	Azioni	%	Valorizzazione
Capital Research & Management Co. (Global Investors) 10,24 %	114 793 989	10,24 %	1 634 M ILa
KSM Mutual Funds Ltd. 1,121 %	12 569 244	1,121 %	179 M ILa
Migdal Mutual Funds Ltd. 0,5102 %	5 719 493	0,5102 %	81 M ILa
Amir Elstein 0,1849 %	2 073 223	0,1849 %	30 M ILa
Kåre Schultz 0,1782 %	1 997 707	0,1782 %	28 M ILa
Excellence Nessuah Mutual Funds Management Ltd. 0,1622 %	1 817 855	0,1622 %	26 M ILa
Roberto Mignone 0,1405 %	1 574 575	0,1405 %	22 M ILa
I. G. Investment Management Ltd. 0,0454 %	508 436	0,0454 %	7 M ILa
IBI Mutual Funds Management (1978) Ltd. 0,0405 %	453 548	0,0405 %	6 M ILa
Eurizon Capital SGR SpA 0,0393 %	440 794	0,0393 %	6 M ILa

Nome	Azioni	%	Valorizzazione
Ion Asset Management Ltd. 3,597 %	40 327 407	3,597 %	569 M ILa
BlackRock Advisors LLC 3,247 %	36 399 055	3,247 %	514 M ILa
Lingotto Investment Management LLP 3,074 %	34 457 656	3,074 %	486 M ILa
THE PHOENIX HOLDINGS LTD. 3,067 %	34 383 192	3,067 %	485 M ILa
CLAL INSURANCE ENTERPRISES HOLDINGS LTD. 2,926 %	32 804 131	2,926 %	463 M ILa
MIGDAL INSURANCE AND FINANCIAL HOLDINGS LTD. 2,580 %	28 919 540	2,580 %	408 M ILa
HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD 2,545 %	28 533 099	2,545 %	403 M ILa
MENORA MIVTACHIM HOLDINGS LTD 2,509 %	28 128 744	2,509 %	397 M ILa
Slate Path Capital LP 2,340 %	26 231 184	2,340 %	370 M ILa
Rubric Capital Management LP 1,626 %	18 226 601	1,626 %	257 M ILa

Nome	Azioni	%	Valorizzazione
MEDIKA D.D. 25.32%	7 646	25.32%	61 106 834 $

Teva Pharmaceutical Industries Ltd.

124 Dvora HaNevi'a Street

6944020, Tel Aviv

+972 3 914 8213

http://www.tevapharm.com

Indirizzo Teva Pharmaceutical Industries Limited(TEVA)

Nome	Categoria e settore
Teva Pharmaceutical Finance Co. BV	Finance/Rental/Leasing
Teva Pharmaceutical Finance Netherlands III BV	Finance/Rental/Leasing
Teva Pharmaceutical Finance Netherlands II BV	Finance/Rental/Leasing
Teva Pharmaceuticals USA, Inc. Teva Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Teva Pharmaceuticals USA, Inc. engages in the manufacturing and marketing of generic pharmaceuticals. The firm also provides medical affairs, quality plus safety and trade partner services. The company was founded in 1985 and is headquartered in Parsippany, NJ.	Pharmaceuticals: Major
Teva Pharmaceutical Finance IV BV	Finance/Rental/Leasing
Teva Finance Services BV
Teva Finance Services II BV
Actavis Holding Asia BV Actavis Holding Asia BV Financial ConglomeratesFinance Part of AbbVie, Inc., Actavis Holding Asia BV operates as a holding Dutch company. The private company is based in Haarlem, Netherlands.	Financial Conglomerates
Watson Pharma Pvt Ltd. Watson Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., Watson Pharma Pvt Ltd. is a pharmaceutical company founded in 2005. The private company is based in Mumbai, India. The Indian company manufactures and supplies pharmaceutical products.	Pharmaceuticals: Major
Teva Czech Industries sro Teva Czech Industries sro Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., Teva Czech Industries sro develops drugs for pharmaceutical preparation. The private company is based in Opava, Czechia. Jiri Urbanec has been the CEO of the Czech company since 2006.	Pharmaceuticals: Major
Teva Pharmaceutical Finance Netherlands IV BV	Finance/Rental/Leasing
Actavis Pharma Development Centre Pvt Ltd. Actavis Pharma Development Centre Pvt Ltd. Pharmaceuticals: GenericHealth Technology Founded in 2006, Actavis Pharma Development Centre Pvt Ltd. is a subsidiary of AbbVie, Inc. that develops, manufactures, and sells generic pharmaceutical products. The private company is based in Mumbai, India.	Pharmaceuticals: Generic
Actavis Pharma Pvt Ltd. Actavis Pharma Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., Actavis Pharma Pvt Ltd. is a pharmaceutical company founded in 2004. The private company manufactures pharmaceutical products and is based in Mumbai, India.	Pharmaceuticals: Major
Teva Pharmaceutical & Chemical Industries India Pvt Ltd. Teva Pharmaceutical & Chemical Industries India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Founded in 2003, Teva Pharmaceutical & Chemical Industries India Pvt Ltd. is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in New Delhi, India and is a subsidiary of Teva Pharmaceutical Industries Ltd.	Pharmaceuticals: Major
Teva Pharmaceutical Industries Teva Pharmaceutical Industries Pharmaceuticals: GenericHealth Technology Part of Teva Pharmaceutical Industries Ltd., the Indian company manufactures and wholesales pharmaceutical products. The private company is located in India.	Pharmaceuticals: Generic
Tevapharm India Pvt Ltd. Tevapharm India Pvt Ltd. Pharmaceuticals: GenericHealth Technology Tevapharm India Pvt Ltd. was founded in 2000 and develops and produces generic and other pharmaceutical medicines. The private company is based in Mumbai, India.	Pharmaceuticals: Generic

Rating Trading

Rating Investimento

ESG Refinitiv

Altri rating

Vendita

Buy

Raccomandazione media

Accumulate

Numero di analisti

Ultimo prezzo di chiusura

13,81 USD

Prezzo obiettivo medio

15,74 USD

Differenza / Target Medio

+13,95%

Consenso

Revisioni delle Stime

Calendario della società

Biotecnologia/Farmaceutici

Biotecnologia/Farmaceutici

Prodotti farmaceutici

Prodotti farmaceutici - Altri

	Variaz. 1 gen.	Capi.
ELI LILLY AND COMPANY	+25,83%	661 Mrd
NOVO NORDISK A/S	+27,00%	566 Mrd
JOHNSON & JOHNSON	-6,76%	352 Mrd
MERCK & CO., INC.	+20,34%	332 Mrd
ABBVIE INC.	+3,00%	283 Mrd
ASTRAZENECA PLC	+13,09%	231 Mrd
NOVARTIS AG	+5,46%	200 Mrd
ROCHE HOLDING AG	-9,61%	195 Mrd
AMGEN INC.	-6,26%	145 Mrd

Prodotti farmaceutici - Altri